A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
Phase 3
Completed
NCT05138250
| Condition | COPD |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
|---|
| Status | Completed |
|---|
| Enrollment | 31 participants |
|---|
| Interventions | Mepolizumab 100 MG |
|---|
| Start date | May 8, 2022 |
|---|
| Completion date | May 8, 2025 |
|---|
| Results posted | May 7, 2026 |
|---|
Summary
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab. This is a licenced medication for asthma. Mepolizumab is a monoclonal antibody that acts through interleukin-5 (IL-5) antagonism to reduce blood eosinophil levels and is effective at reducing exacerbations in asthmatics. To determine whether mepolizumab may be an effective treatment in people with COPD and "asthmatic type" inflammation participants will have MRI scans before the treatment, after 12 weeks and after a year to see how the drug affects inflammation. The investigators will also compare our measurements with the number of exacerbations people get (measured by diaries), with measures of their quality of life (using a questionnaire), and with ordinary laboratory breathing tests. The investigators are especially interested to know if the reduction in inflammation early on after 12 weeks is associated with fewer exacerbations and better quality of life over the year.
Change in Percentage Ventilated Defect Percent (VDP)
Baseline to 12 weeks of treatment · % change in VDP
| Treatment Arm (All Participants, Not Randomised) | -0.14 ± 6.5 % change in VDP |
|---|
Change in Pulmonary Inflammation
From Baseline to 12 weeks of treatment · ratio
| Participants Completing Assessment 2 | -0.00009 ratio |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.